Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
An International Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 0.5% and 2% PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
Sponsor: Department for International Development, United Kingdom
Listed as NCT00262106, this PHASE3 trial focuses on Chlamydial Infections and Genital Herpes and remains completed. Sponsored by Department for International Development, United Kingdom, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department for International Development, United Kingdom
- Endo Pharmaceuticals
- Medical Research Council
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bertsham, South Africa
- • Entebbe, Uganda
- • Mazabuka, Zambia
- • Mtubatuba, South Africa
- • Mwanza, Tanzania
- • Westville, South Africa